Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol
Abnormal uterine bleeding is common in Thai women. Fractional curettage is an diagnostic procedure of this condition. Traditionally, fractional curettage is performed under local anesthesia such as paracervical nerve block or intravenous meperidine.
Cervical dilatation using "metal cervical dilator" is a common method prior to perform fractional curettage. However, complication from this procedure can be occurred frequently, for example, uterine perforation, false tract formation and laceration of cervix.
Misoprostol is a prostaglandin E1 analogue which is commonly used in obstetrics and gynecology. Misoprostol transforms cervical component causing cervical ripening. This is very helpful for transcervical procedure because cervical dilatation is usually omitted. It can be prescribed in many route and sublingual route is the most effectiveness. Moreover, WHO supports the use of misoprostol in obstetrics and gynecology practice.
The hypothesis of this study is that "Misoprostol 200 micrograms sublingually is effective for cervical ripening before performing fractional curettage in patients with abnormal uterine bleeding" Double blind randomised controlled trial was performed using 26 patients in each group.
Abnormal Uterine Bleeding Unrelated to Menstrual Cycle
Drug: Vitamin B6
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding (AUB) Using Sublingual Misoprostol 200 Mcg: A Randomized, Double Blind, Placebo-controlled Trial|
- efficacy of 200 microgram Misoprostol for cervical ripening prior to performing fractional curettage in patients with abnormal uterine bleeding [ Time Frame: 1 Year ] [ Designated as safety issue: No ]an efficacy of sublingual misoprostol in this study was dilatation of uterine cervix which was measured by a diameter of MVA cannula in millimeters.
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||June 2013|
|Estimated Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
200 mcg Misoprostol SL 1 hour prior to fractional curettage
Other Name: Cytotec
Placebo Comparator: Vitamin B6
100 mg Vitamin B6 SL 1 hr prior to fractional curettage
Drug: Vitamin B6
Other Name: Besix
Please refer to this study by its ClinicalTrials.gov identifier: NCT01762319
|Contact: Korakot Sirimai, Dr.||(66)email@example.com|
|Faculty of Medicine Siriraj Hospital Mahidol University||Recruiting|
|Bangkok, Thailand, 10700|
|Contact: Korakot Sirimai, Dr. (66)81-6140655 firstname.lastname@example.org|
|Principal Investigator: Korakot Sirimai, Dr.|
|Sub-Investigator: Tripop Lertbunnaphong, Dr.|
|Principal Investigator:||Korakot Sirimai, MD||Mahidol University|